Tag:

Hepatitis C

Latest Headlines

Latest Headlines

Warning to Gilead, AbbVie and BMS: France has a new tax for pricey hep C meds

European countries are known for wresting price cuts from drugmakers. Usually, it's a straightforward cost-effectiveness argument. But France has come up with a new strategy: Arm-twisting taxes.

Flagging Novartis drops out of hep C race, punting a $440M Enanta pact

According to the biotech Enanta, you can count Novartis out of the race to develop next-gen hepatitis C cocktails. The pharma giant has bowed out of its partnership with Enanta on an NS5A inhibitor code-named EDP-239, which attracted a $440 million deal--including $36 million upfront--back in 2012.

J&J makes a splash in hep C with a $1.75B deal for Alios

Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.

Gilead nears EU approval for the next big thing in hep C

Gilead Sciences, already a trailblazer in hepatitis C treatment, is creeping up on its next milestone: approval for a combination therapy that promises to cure the majority of patients without the need for painful injections.

Real-world hep C patients drop off pricey Sovaldi, CVS study finds

CVS Health has some hard data on Sovaldi's excursion from the Gilead Sciences clinic and into the world. It's not encouraging: More than four times as many real-world patients are dropping off the pricey hepatitis C treatment than in clinical trials.

Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C

Want a window into the future of hepatitis C drug marketing? Keep an eye on Europe. Bristol-Myers Squibb bagged European approval for its hepatitis C fighter Daklinza (daclatasvir) Wednesday, setting the company up for head-to-head competition with Gilead Sciences' upcoming combo drug.

Don't worry about a hep C pricing war, analysts tell Gilead-watchers

No price war on hepatitis C drugs? That would be a disappointment to payers worried about the cost of treating millions of patients with super-expensive, yet highly effective drugs. But to investors, that reassurance sounds really good.

Gilead fends off Roche as hep C heavyweights fight for blockbuster rights

Gilead Sciences convinced an panel of arbitrators that rival Roche had no legitimate claims on Sovaldi, its record-setting hepatitis C treatment, but the antiviral pioneer still faces patent spats with a host of challengers looking to cash in on next-generation combo therapies for the disease.

Achillion shoulders its way into the hep C race with strong early data

Biotech Achillion Pharmaceuticals is working to get its name on the short list of blockbuster hepatitis C contenders, revealing promising Phase II data for a combination of its antiviral with Gilead Sciences' leading Sovaldi.

Sovaldi forces Incivek off the hep C market as Vertex calls it quits

Bye-bye, Incivek. Just three years after nabbing the "fastest drug launch ever" award, maker Vertex is discontinuing the hepatitis C med on withering demand. For that, the Cambridge-based company has Gilead Sciences--owner of the new fastest drug launch ever--to thank.